Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

The development of several highly effective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), along with expanding knowledge about mechanisms of acquired resistance and tumour evolution offers the possibility of sequential therapy in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Currently, the optimal sequence of therapy is unknown. Five EGFR TKIs are available: the first-generation reversible TKIs, erlotinib and gefitinib; the second-generation irreversible ErbB family blockers, afatinib and dacomitinib; and the third-generation EGFR-wild-type sparing, irreversible TKI, osimertinib.

Source: Lung Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Keunchil Park, Jaafar Bennouna, Michael Boyer, Toyoaki Hida, Vera Hirsh, Terufumi Kato, Shun Lu, Tony Mok, Kazuhiko Nakagawa, Kenneth O ’Byrne, Luis Paz-Ares, Martin Schuler, Denis Moro Sibilot, Eng-Huat Tan, Hiroshi Tanaka, Yi-Long Wu, James C-H. Yang, Source Type: research